Enantioselective resolution of thyroxine hormone by high-performance liquid chromatography utilizing a highly fluorescent chiral tagging reagent

Chirality

Volumn 19, Issue 8, 2007, Pages 625-631

  Jin, Dongri ^a,b   Zhang, Meina ^b   Jin, Shanji ^b   Lee, Min Kwon ^a   Song, Goon Cheol ^a   Back, Gernho ^a   Lee, Yong Ill ^a  

^a Changwon National University   (South Korea)

^b YANBIAN UNIVERSITY   (China)

Author keywords

Fluorescence detection; Fluorescent chiral tagging reagent; HPLC; Precolumn derivatization; Thyroxine enantiomers

Indexed keywords

4 (3 ISOTHIOCYANATOPYRROLIDIN 1 YL) 7 (N,N DIMETHYLAMINOSULFONYL) 1,3 BENZOXADIAZOLE; ACETONITRILE; PYRROLIDINE DERIVATIVE; REAGENT; THYROXINE; UNCLASSIFIED DRUG; WATER;

CALIBRATION; CHIRALITY; CONFERENCE PAPER; DERIVATIZATION; DIASTEREOISOMER; ELECTROSPRAY MASS SPECTROMETRY; ENANTIOMER; ENANTIOSELECTIVITY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; RACEMIZATION; SERUM; TANDEM MASS SPECTROMETRY; THYROXINE BLOOD LEVEL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; FLUORESCENT DYES; HUMANS; ISOTHIOCYANATES; OXADIAZOLES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; THYROXINE;

EID: 34447552555     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20414     Document Type: Conference Paper

References (25)

1. Aboul-Enein HY, Wainer IW, editors. The impact of stereochemistry on drug development and use (Chemical Analysis Series, Vol. 142). New York: Wiley; 1997.
2. Caldwell J. Importance of stereospecific bioanalytical monitoring in drug development. J Chromatogr A 1996;719:3-13.
3. FDA. Policy statement for the development of new stereoisomeric drugs, 1992. Available at http://www.fda.gov/cder/guidance/stereo.htm.
4. Lum SM, Nicoloff JT, Spencer CA, Kaptein EM. Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man. J Clin Invest 1984;73:570-575.
5. Finn MG. Emerging methods for the rapid determination of enantiomeric excess. Chirality 2002;14:534-540.
6. Tsukamoto M, Kagan HB. Recent advances in the measurement of enantiomeric excess. Adv Synth Catal 2000;344:453-463.
7. Tsourkas A, Hofstetter O, Hofstetter H, Weissleder R, Josephson L. Magnetic relaxation switch immunosensors detect enantiomeric impurities. Angew Chem Int Ed Engl 2004;43:2395-2399.
8. Gika H, Lämmerhofer M, Papadoyannis I, Lindner W. Direct separation and quantitative analysis of thyroxine and triiodothyronine enantiomers in pharmaceuticals by high-performance liquid chromatography. J Chromatogr B 2004;800:193-201.
9. Gubitz G, Juffmann F. Resolution of the enantiomers of thyroid hormones by high-performance ligand-exchange chromatography using a chemically bonded chiral stationary phase. J Chromatogr A 1987;404:391-393.
10. Hay ID, Annesley TM, Jiang NS, Gorman CA. Simultaneous determination of D- and L-thyroxine in human serum by liquid chromatography with electrochemical detection. J Chromatogr A 1982;226:383-390.
11. Ekborg-Ott KH, Kullman JP, Wang X, Gahm K, He L, Armstrong DW. Evaluation of the macrocyclic antibiotic avoparcin as a new chiral selector for HPLC. Chirality 1998;10:627-660.
12. 3) from serum using a sequential injection analysis/immunosensor system. J Immunoassay Immunochem 2004;25: 183-189.
13. 4). J Immunoassay Immunochem 2002;23: 429-437.
14. Leb G, Lankmayr EP, Goebel R, Pritautz H, Nachtmann F, Knapp G. Stereospecific determination of D-thyroxine and L-thyroxin in serum. Klin Wochenschr 1981;59:861-863.
15. Aboul-Enein HY, Ali I, Hyun MH, Cho YJ, Jin JS. Effect of acidity on the enantiomeric resolution of thyroxine and tocainide by HPLC on a (+)-(18-crown-6)-2,3,11,12-tetracarboxylic acid column. J Biochem Biophys Methods 2002;54:407-413.
16. Abou-Basha LI, Aboul-Enein HY. Enantiomeric separation and optical puritydetermination of thyroxine enantiomers in bulk and pharmaceutical formulations. Pharm Acta Helv 1995;70:237-240.
17. Rong W, Jia ZP, Hu XL, Xu LT, Li YM, Chen LR. Determination of serum thyroxine enantiomers in patients by liquid chromatography with a chiral mobile phase. J Chromatogr B 2003;785:353-359.
18. Lankmayr E, Budna K, Nachtmann FJ. Separation of enantiomeric iodinated thyronines by liquid chromatography of diastereomers. J Chromatogr A 1981;198:471-479.
19. Jin D, Takehana K, Toyo'oka T. Chiral separation of racemic thiols based on diastereomer formation with a fluorescent chiral tagging reagent by reversed-phase liquid chromatography. Anal Sci 1997;13:113-115.
20. Jin D, Nagakura K, Murofushi S, Miyahara T, Toyo'oka T. Total resolution of 17 DL-amino acids labeled with a fluorescent chiral reagent, 4-(3-isothiocyanatopyrroli- din-1-yl)-7-(N,N-dimethylaminosulfonyl-2,1,3- benzoxadiazole, by high-performance liquid chromatography. J Chromatogr A 1998;822:215-224.
21. Jin D, Miyahara T, Oe T, Toyo'oka T. Determination of D-amino acids labeled with fluorescent chiral reagent, R(-)- and S(+)-4-(3- isothiocyanatopyrrolidin-1-yl)-7-(N,N-dimethylaminosulfonyl-2,1, 3-benzoxadiazoles, in biological and food samples by liquid chromatography. Anal Biochem 1999;269:124-132.
22. Smith DJ, Biesemeyer M, Yaciw C. The separation and determination of liothyronine and levothyroxine in tablets by reversed-phase high performance liquid chromatography. J Chromatogr Sci 1981; 19:72-78.
23. Richheimer SL, Amer TM. Stability-indicating assay, dissolution, and content uniformity of Tahani M. J Pharm Sci 1983;72:1349-1351.
24. Brower JF, Toler DY, Reepmeyer JC. Determination of sodium levothyroxine in bulk, tablet, and injection formulations by HPLC. J Pharm Sci 1984;73:1315-1317.
25. Takahashi M, Nagashima M, Shigeoka S, Kamimura H, Kamata K. Determination of thyroid hormones in pharmaceutical preparations, after derivatization with 9-anthroynitile, by high-performance liquid chromatography with fluorescence detection. J Chromatogr A 2002; 958:299-303.